| Program | Target Indication | Drug Type | Discovery | Preclinical | Clinical | Collaboration Partners |
|
|---|---|---|---|---|---|---|---|
| BMD-001 | AD, ALS, and PD | BDDSTM – ASO (miR-485-3p Antagomir) |  |
||||
| BMD-002 | Epilepsy | BDDSTM – ASO (Undisclosed) |  |
||||
| BMD-003 | MAFLD / Obesity | LNA – Gapmer (Undisclosed) | |
||||
| BIOK-001 | Neuroinflammatory disease | BDDSTM – Undisclosed |  |
||||
| BIOK-007 | Tauopathy | BDDSTM – siRNA (Undisclosed) | |
||||
| BIOK-008 | Synucleinopathy | BDDSTM – siRNA | |
||||
PIPELINE
Our Programs
The limitless potential of innovative drug development based on the BDDS™ platform.
Our BDDS™ platform technology offers boundless potential for innovative genetic medicines by safely delivering a variety of genetic therapeutics to specific organs. Particularly renowned for its exceptional ability to target brain cells, the BDDS™ platform enables the development of treatments for brain disorders and rare central nervous system diseases.
Leveraging the scalability of the BDDS™ platform, we are building diverse pipelines through collaboration with partners.
This enables us to further advance the development of groundbreaking new drugs.
BDDSTM = Brain Targeting Drug Delivery System
AD = Alzheimer’s Disease, ALS = Amyotrophic lateral sclerosis, PD = Parkinson Disease
MAFLD = Metabolic Dysfunction-Associated Fatty Liver Disease. LNA-GAPMER = Locked Nucleic Acid (LNA)-Gapmer are a class of antisense molecules designed for sequence-specific silencing of RNA.
Stay Connected
